Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in hu… Read more
Finch Therapeutics Group Inc (FNCH) - Net Assets
Latest net assets as of June 2024: $14.22 Million USD
Based on the latest financial reports, Finch Therapeutics Group Inc (FNCH) has net assets worth $14.22 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($45.58 Million) and total liabilities ($31.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.22 Million |
| % of Total Assets | 31.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9.75 |
Finch Therapeutics Group Inc - Net Assets Trend (2019–2024)
This chart illustrates how Finch Therapeutics Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Finch Therapeutics Group Inc (2019–2024)
The table below shows the annual net assets of Finch Therapeutics Group Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.08 Million | -60.33% |
| 2023-12-31 | $22.89 Million | -76.09% |
| 2022-12-31 | $95.71 Million | -52.67% |
| 2021-12-31 | $202.22 Million | +311.27% |
| 2020-12-31 | $-95.72 Million | -60.78% |
| 2019-12-31 | $-59.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Finch Therapeutics Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30077800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.02% |
| Other Components | $373.35 Million | 4112.23% |
| Total Equity | $9.08 Million | 100.00% |
Finch Therapeutics Group Inc Competitors by Market Cap
The table below lists competitors of Finch Therapeutics Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DMCC SPECIALITY CHEMICALS LIMITED
NSE:DMCC
|
$21.11 Million |
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
$21.11 Million |
|
Lunnon Metals Ltd
AU:LM8
|
$21.12 Million |
|
Frontier Energy Limited
OTCQB:FRHYF
|
$21.12 Million |
|
Neofect Co.Ltd
KQ:290660
|
$21.11 Million |
|
MARINOMED BIOTECH AG INH.
F:93Z
|
$21.09 Million |
|
Tridomain Performance Materials PT
JK:TDPM
|
$21.09 Million |
|
AV Tech Corp
TW:8072
|
$21.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Finch Therapeutics Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,886,000 to 9,079,000, a change of -13,807,000 (-60.3%).
- Net loss of 13,877,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.88 Million | -152.85% |
| Other Changes | $70.00K | +0.77% |
| Total Change | $- | -60.33% |
Book Value vs Market Value Analysis
This analysis compares Finch Therapeutics Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-37.00 | $13.50 | x |
| 2020-12-31 | $-59.49 | $13.50 | x |
| 2021-12-31 | $127.69 | $13.50 | x |
| 2022-12-31 | $60.21 | $13.50 | x |
| 2023-12-31 | $14.26 | $13.50 | x |
| 2024-12-31 | $5.65 | $13.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Finch Therapeutics Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -152.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 5.48x
- Recent ROE (-152.85%) is below the historical average (-104.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -204.39% | 0.10x | 0.00x | $-14.80 Million |
| 2020 | 0.00% | -508.46% | 0.05x | 0.00x | $-29.68 Million |
| 2021 | -27.62% | -301.42% | 0.08x | 1.11x | $-76.08 Million |
| 2022 | -119.78% | -13315.45% | 0.01x | 1.70x | $-124.22 Million |
| 2023 | -326.64% | -69863.55% | 0.00x | 2.42x | $-77.04 Million |
| 2024 | -152.85% | 0.00% | 0.00x | 5.48x | $-14.78 Million |
Industry Comparison
This section compares Finch Therapeutics Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Finch Therapeutics Group Inc (FNCH) | $14.22 Million | 0.00% | 2.21x | $21.11 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |